ArticleJournal of asthma and allergy2026
Persistent Airflow Limitation in Asthma: Clinical Characteristics, Risk Factors, and Long-term Outcomes from a Multicenter Cohort Study.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Persistent airflow limitation (PAL) is an increasingly recognized asthma phenotype, but its prevalence, determinants, and prognostic significance in real-world settings remain unclear. This study evaluated the clinical characteristics and long-term outcomes associated with PAL and its severity in asthma. Methods: Multicenter analysis of combined retrospective and prospective cohorts in South Korea. PAL was defined as post-bronchodilator FEV Results: Among 849 patients with asthma, 640 (75.4%) had PAL. PAL was associated with older age, male sex, lower body mass index, higher smoking intensity, lower FEV Conclusion: PAL and its severity independently predict the risk of severe exacerbations and progressive lung function decline in asthma, underscoring PAL as a key marker of disease progression and a potential target for early intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.